Vivus appoints Ernest Mario to board
This article was originally published in Scrip
Vivus has elected Dr Ernest Mario, who has 40 years' experience in the pharmaceutical industry, to its board of directors. Dr Mario is a former deputy chair and chief executive of Glaxo Holdings, ALZA Corporation and Reliant Pharmaceuticals. He currently serves as a director of Boston Scientific, Celgene Biopharmaceutical and Capina. He is also chair of the American Foundation for Pharmaceutical Education and an advisor to the Ernest Mario School of Pharmacy at Rutgers University.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.